Compare CRDL & GEVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRDL | GEVO |
|---|---|---|
| Founded | 2017 | 2005 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.3M | 474.9M |
| IPO Year | N/A | 2011 |
| Metric | CRDL | GEVO |
|---|---|---|
| Price | $1.04 | $1.87 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $9.00 | $6.42 |
| AVG Volume (30 Days) | 376.9K | ★ 2.8M |
| Earning Date | 03-30-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $120,932,000.00 |
| Revenue This Year | N/A | $913.54 |
| Revenue Next Year | N/A | $11.79 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 675.75 |
| 52 Week Low | $0.77 | $0.92 |
| 52 Week High | $1.59 | $2.95 |
| Indicator | CRDL | GEVO |
|---|---|---|
| Relative Strength Index (RSI) | 52.90 | 45.92 |
| Support Level | $0.98 | $1.76 |
| Resistance Level | $1.09 | $1.90 |
| Average True Range (ATR) | 0.06 | 0.11 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 61.76 | 35.23 |
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
Gevo Inc is a next-generation diversified energy company committed to fueling America's future with cost-effective, drop-in fuels that contribute to energy security, abate carbon, and strengthen rural communities to drive economic growth. Its technology can be used to make a variety of renewable products, including sustainable aviation fuel (SAF), motor fuels, chemicals, and other materials that provide U.S.-made solutions. The business model includes developing, financing, and operating production facilities that create jobs and revitalize communities. It owns and operates an ethanol plant with an adjacent CCS facility, Class VI carbon-storage well, and others. The group is currently developing the world's first large-scale ATJ facility to be co-located at the North Dakota site.